article thumbnail

The social media problem for healthcare

World of DTC Marketing

A year ago, Facebook was making a hard charge to get the pharma business. From my estimates, most of it failed because pharma companies are afraid of misinformation concerning regulations around DTC marketing.

Branding 224
article thumbnail

COVID-19 and the digital pharma marketing revolution

pharmaphorum

The global pandemic has caused pharma companies to invest in digital marketing, as healthcare systems across the world adapt to strict lockdown rules. Healthcare companies have been in the vanguard of this change, with an enormous rise in the use of telehealth and all forms of digital communications.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Another reason change is needed at FDA? Fair balance

World of DTC Marketing

As we have seen over the past few years, Pharma companies are a business, a regulated business, but still a business. To portray patients, mindless people who blindly believe DTC TV ads and rush to their doctor to ask for a product are inaccurate. There was zero mention of fair balance warnings by the groups.

Doctors 165
article thumbnail

Disruption in healthcare is coming

World of DTC Marketing

PBMs, insurers, pharma companies, and hospitals don’t want to give up their profits even if it’s better for the general population. The company has hired former senior health regulators to help it navigate America’s healthcare bureaucracy. . Google is also giving health records another whirl.

Pharmacy 227
article thumbnail

High hopes as Inventiva takes NASH contender into phase 3

pharmaphorum

The regulator said it wanted more long-term safety and efficacy data from the REGENERATE study before making a final decision on the drug, which had been expected to be the first entrant into a likely multi-billion dollar market niche. billion annually if approved.

article thumbnail

Team behind RECOVERY trial of COVID drugs casts its net wider

pharmaphorum

. “The cost of developing a new drug is extortionately high,” said Landray, adding that a very large proportion of those costs is in phase 3, and that means many promising therapies may never be taken forward by pharma companies.

Trials 96
article thumbnail

Pfizer deal paves way for approval of ImaginAb’s cancer imaging tech

pharmaphorum

The California-based company has signed a non-exclusive license with Pfizer to supply its 89Zr CD8 Immuno-PET agent, which can be used to image CD8 T cells in cancer patients. Equally important to the company is the safety data gathered as the technology is used as the pharma companies use it to guide development of cancer immunotherapies.

Doctors 51